March 16 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 EMANATE TRIAL
RHYTHM PHARMACEUTICALS INC - EMANATE PHASE 3 TRIAL DOES NOT MEET PRIMARY ENDPOINTS
RHYTHM PHARMACEUTICALS INC - NO NEW SAFETY SIGNALS OBSERVED WITH SETMELANOTIDE IN EMANATE TRIAL
RHYTHM PHARMACEUTICALS INC: PLANS TO CONTINUE ANALYSIS OF EMANATE DATASET & EVALUATE POTENTIAL CLINICAL DEVELOPMENT PATHS FORWARD